SCHEMBL6445103

SCHEMBL6445103

CC(C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)[C@H](O)[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)C

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSD P07339 4/20 0.76
CTSL P07711 2/20 0.56
CTSS P25774 2/20 0.56
TRPM8 Q7Z2W7 1/20 0.56
CA2 P00918 2/20 0.55
CASP3 P42574 1/20 0.55
REN P00797 1/20 0.55
CTSK P43235 3/20 0.53
CTSB P07858 1/20 0.53
ECE1 P42892 2/20 0.53
CA5A P35218 1/20 0.53
MME P08473 1/20 0.53
PSMB11 A5LHX3 1/20 0.52
PSMA7 O14818 1/20 0.52
PSMB1 P20618 1/20 0.52
PSMA1 P25786 1/20 0.52
PSMA2 P25787 1/20 0.52
PSMA3 P25788 1/20 0.52
PSMA4 P25789 1/20 0.52
PSMB8 P28062 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6446151 1.00 CTSD (0.76) CTSDCTSLCTSSTRPM8CA2
SCHEMBL9232828 1.00 CTSD (0.76) CTSDCTSLCTSSTRPM8CA2
SCHEMBL6446780 1.00 CTSD (0.76) CTSDCTSLCTSSTRPM8CA2
SCHEMBL9740721 1.00 CTSD (0.76) CTSDCTSLCTSSTRPM8CA2
SCHEMBL6132144 0.98 CTSD (0.76) CTSDCTSLCTSSTRPM8CA2
SCHEMBL6449641 0.98 CTSD (0.76) CTSDCTSLCTSSTRPM8CA2
Acetic Acid SCHEMBL7270658 0.95 CTSD (0.73) CTSDCTSLCTSSTRPM8CA2
SCHEMBL6454320 0.93 CTSD (0.68) CTSDCTSLCTSSTRPM8CA2
SCHEMBL7342149 0.93 CTSD (0.68) CTSDCTSLCTSSTRPM8CA2
SCHEMBL6448985 0.93 CTSD (0.68) CTSDCTSLCTSSTRPM8CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0839798-B1 Intermediates for preparating non-peptide retroviral protease inhibitors ABBOTT LAB (US) 2005-08-17 EP claimed
EP-0839798-A2 Intermediates for preparating non-peptide retroviral protease inhibitors ABBOTT LABORATORIES (US) 1998-05-06 EP claimed
US-20250282803-A1 DIDEHYDRO-3'-DEOXY-4'-ETHYNYLTHYMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS ROME THERAPEUTICS, INC. 2025-09-11 US disclosed
US-20250145654-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS, INC. 2025-05-08 US disclosed
EP-4511381-A1 DIDEHYDRO-3'-DEOXY-4'-ETHYNYLTHYMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Rome Therapeutics, Inc. (US) 2025-02-26 EP disclosed
EP-4493573-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE Rome Therapeutics, Inc. (US) 2025-01-22 EP disclosed
US-12187758-B2 Compounds and methods for treating disease ROME THERAPEUTICS, INC. (US) 2025-01-07 US disclosed
US-20240366649-A1 4-ETHYNYL-3-HYDROXY-TETRAHYDROFURANYL-ADENINE PHOSPHORAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS ROME THERAPEUTICS, INC. 2024-11-07 US disclosed
WO-2024107859-A1 CYCLOPENTENE-OXYMETHYLENE PHOSPHONAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS ROME THERAPEUTICS, INC. (US) 2024-05-23 WO disclosed
WO-2024107850-A1 HALO-DEHYDRO-3'-DEOXYURACIL PHOSPHORAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS ROME THERAPEUTICS, INC. (US) 2024-05-23 WO disclosed
WO-2024103016-A1 4'-HALOMETHYL-CYTIDINE PHOSPHORAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS ROME THERAPEUTICS, INC. (US) 2024-05-16 WO disclosed
EP-0839798-B1 Intermediates for preparating non-peptide retroviral protease inhibitors ABBOTT LAB (US) 2005-08-17 EP disclosed
EP-0839798-A3 Intermediates for preparating non-peptide retroviral protease inhibitors ABBOTT LABORATORIES (US) 1998-09-09 EP disclosed
EP-0402646-B1 Retroviral protease inhibiting compounds ABBOTT LAB (US) 1998-07-22 EP disclosed
EP-0839798-A2 Intermediates for preparating non-peptide retroviral protease inhibitors ABBOTT LABORATORIES (US) 1998-05-06 EP disclosed
EP-0839798-A2 Intermediates for preparating non-peptide retroviral protease inhibitors ABBOTT LABORATORIES (US) 1998-05-06 EP disclosed
US-5670675-A Retroviral protease inhibiting compounds ABBOTT LABORATORIES (US) 1997-09-23 US disclosed
US-5545750-A TREATING HUMAN IMMUNODEFICIENCY VIRUS ABBOTT LABORATORIES (US) 1996-08-13 US disclosed
US-5142056-A Human immunodeficiency virus protease inhibitor ABBOTT LABORATORIES (US) 1992-08-25 US disclosed
EP-0402646-A1 Retroviral protease inhibiting compounds ABBOTT LABORATORIES (US) 1990-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366649-A1 4-ETHYNYL-3-HYDROXY-TETRAHYDROFURANYL-ADENINE PHOSPHORAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS HPRT1, DTYMK, POLI CTSD 3671/4885CTSL 2982/4885CTSS 3218/4885
US-20250282803-A1 DIDEHYDRO-3'-DEOXY-4'-ETHYNYLTHYMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS DTYMK, DCK, POLK CTSD 2706/4885CTSL 2661/4885CTSS 2653/4885
US-20250145654-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE EHMT1, POLRMT, RNASE1 CTSD 2689/4885CTSL 4211/4885CTSS 2608/4885
US-12187758-B2 Compounds and methods for treating disease EHMT1, POLRMT, RNASE1 CTSD 2689/4885CTSL 4211/4885CTSS 2608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.